PREVENT: Eculizumab May Lower Relapse Risk in NMOSD

Use of eculizumab resulted in significantly greater relapse reduction over placebo in patients with neuromyelitis optica spectrum disorder (NMSOD), new findings from the phase 3 PREVENT trial show.
Medscape Medical News

Source link

Related posts

Reader response: To harvest?: A reality-based ethical dilemma and fictional dialogue


Differential Mechanisms Underlying Antidepressant Responses of Ketamine and Imipramine.


neurosciencestuff: (Image caption: A stylized microscopy image…


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy